文献速递泌尿生殖腹部US

SonoVue与Sonazoid超声造影评价肾脏肿块的对比研究

Evaluation of Renal Masses Using Contrast-Enhanced Ultrasound with Sonovue and Sonazoid.
PubMed 文献 · Ultrasound Med Biol · 2024-10-18

研究纳入57例肾脏肿块患者,按术后病理分为ccRCC、pRCC、非ccRCC及非pRCC恶性组和良性组,比较SonoVue与Sonazoid超声造影的增强特征并评估其对ccRCC的诊断效能。两种造影剂在四组中的增强特征无显著差异(p > .05),鉴别ccRCC与非ccRCC的敏感度分别为88.6%和85.7%,特异度分别为76.5%和88.2%,各诊断指标间无统计学显著差异(p > .05)。

要点

  • SonoVue与Sonazoid超声造影在肾脏肿块血管期的增强特征相似,四组间无显著差异(p > .05)。
  • 两者鉴别ccRCC与非ccRCC均有较好诊断效能,SonoVue敏感度88.6%、特异度76.5%。
  • Sonazoid敏感度85.7%、特异度88.2%,两法各诊断指标间无统计学显著差异(p > .05)。

核心结论

  • SonoVue与Sonazoid超声造影在评价肾脏肿块血管期增强特征方面表现相似。
  • 两种造影剂超声造影对ccRCC与非ccRCC的鉴别诊断均显示出较好的诊断效能。

研究设计与样本

  • 研究纳入57例符合条件患者,依据术后组织病理诊断分为ccRCC组、pRCC组、非ccRCC及非pRCC恶性组和良性肿块组。
  • 分析各组肾脏肿块在SonoVue与Sonazoid超声造影后的增强特征,并确定两种造影剂对ccRCC与非ccRCC的诊断效能。

关键影像表现/征象

  • 四组肾脏肿块在SonoVue与Sonazoid超声造影中的增强特征无显著差异(p > .05)。

诊断标准与关键数值

  • SonoVue超声造影鉴别ccRCC与非ccRCC:敏感度88.6%、特异度76.5%、准确率84.6%、阳性预测值88.6%、阴性预测值76.5%。
  • Sonazoid超声造影鉴别ccRCC与非ccRCC:敏感度85.7%、特异度88.2%、准确率86.5%、阳性预测值93.8%、阴性预测值75%。
  • 两种方法各诊断效能指标间无统计学显著差异(p > .05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To explore the differences between SonoVue and Sonazoid contrast-enhanced ultrasound (CEUS) in evaluating enhancement features of renal masses and determine the diagnostic value of CEUS in clear cell renal cell carcinoma (ccRCC).

METHODS: A total of 57 eligible patients were enrolled and divided into the ccRCC, papillary renal cell carcinoma (pRCC), non-ccRCC and non-pRCC malignancy groups, and benign mass groups based on their postsurgical histopathologic diagnosis. The enhancement features of renal masses following SonoVue and Sonazoid CEUS in each group were analyzed. Diagnostic efficiencies of SonoVue and Sonazoid CEUS for ccRCC and non-ccRCC were determined.

RESULTS: There were no significant differences in the enhancement features of renal masses with SonoVue and Sonazoid imaging in the four groups (p > .05). Both SonoVue CEUS and Sonazoid CEUS showed good diagnostic performance for the differential diagnosis of ccRCC and non-ccRCC, with sensitivities of 88.6% and 85.7%, specificities of 76.5% and 88.2%, accuracies of 84.6% and 86.5%, positive predictive values of 88.6% and 93.8%, and negative predictive values of 76.5% and 75%, respectively. There were no statistically significant differences in any of the diagnostic performance indices between the two methods (p > .05).

CONCLUSION: The CEUS features of SonoVue and Sonazoid in evaluating renal masses were similar in the vascular phase. Both SonoVue and Sonazoid CEUS showed good diagnostic performance for the differential diagnosis of ccRCC and non-ccRCC.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Zhang H, Guo G, Zhu R, et al. Evaluation of Renal Masses Using Contrast-Enhanced Ultrasound with Sonovue and Sonazoid. Ultrasound Med Biol. 2024. PMID: 39426844. doi:10.1016/j.ultrasmedbio.2024.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。